PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34959453-2	2021	Since both are substrates of P-glycoprotein (P-gp), and sorafenib is also an inhibitor of P-gp, their co-administration may affect their pharmacokinetics, and thus the safety and efficacy of cancer therapy.	Sorafenib	56-65	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	90-94	
32776310-2	2020	Sorafenib was moderately transported by P-glycoprotein (P-gp) and more efficiently by breast cancer resistance protein.	Sorafenib	0-9	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	40-54	
32776310-2	2020	Sorafenib was moderately transported by P-glycoprotein (P-gp) and more efficiently by breast cancer resistance protein.	Sorafenib	0-9	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	56-60	
26582036-0	2016	The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4.	Sorafenib	29-38	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	51-65	
26582036-2	2016	The aim of this study was to investigate the potential drug-drug interaction of sorafenib mediated by P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4).	Sorafenib	80-89	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	102-116	
26582036-2	2016	The aim of this study was to investigate the potential drug-drug interaction of sorafenib mediated by P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4).	Sorafenib	80-89	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	118-122	
26582036-12	2016	In conclusion, the drug-drug interaction of sorafenib might happen when sorafenib was co-administered with P-gp or CYP3A4 inhibitors.	Sorafenib	44-53	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	107-111